Belluscura Regulatory News (BELL)

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU) NO.596/2014, WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").

Belluscura plc

("Belluscura", the "Company" or the "Group")

Allotment of shares

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announced on 13 May 2022 the result of a Placing to raise approximately £6.0 million by way of the issue of 7,058,824 Placing Shares at an issue price of 85 pence per ordinary share.

The Placing Shares will be issued credited as fully paid and will rank pari passu with the Existing Ordinary Shares and represent approximately 6.2 per cent. of the Existing Ordinary Shares.

The Company has allotted, subject to First Admission (as defined below), 1,137,630 EIS/VCT Placing Shares and, subject to Second Admission (as defined below), 5,921,194 General Placing Shares.

Admission and dealings

Application has been made for 1,137,630 EIS/VCT Placing Shares, issued pursuant to the Placing, to be admitted to trading on AIM which is expected to occur at 8.00 a.m. on 18 May 2022 ("First Admission").

Application has also been made for 5,921,194 General Placing Shares, also issued pursuant to the Placing, to be admitted to trading on AIM which is expected to occur at 8.00 a.m. on 19 May 2022 ("Second Admission").

Total voting rights

Following First Admission, the issued share capital of the Company will comprise 115,306,407 Ordinary Shares, none of which are held in treasury. Therefore, following First Admission, the total number of Ordinary Shares with voting rights in the Company will be 115,306,407 Ordinary Shares, which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Following Second Admission, the issued share capital of the Company will comprise 121,227,601 Ordinary Shares, none of which are held in treasury. Therefore, following Second Admission, the Enlarged Share Capital of the Company and total number of Ordinary Shares with voting rights in the Company will be 121,227,601 Ordinary Shares, which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Capitalised terms used in this announcement have the meanings given to them in the Launch Announcement of 12 May 2022, unless the context provides otherwise.

For further information please contact: